Clinical trials: Hepatitis, Viral, Human
Chronic Hepatitis B
A Phase II/III of Hepenofovir Fumarate Tablets (HTS) for Chronic Hepatitis B
UsingTAF as the control, the nvestigators aim to further explore the efficacy and safety of different dosages of HTS in the treatment of patients with chronic hepatitis B; ultimately, the nvestigators determine the optimal…
- Trial name
- NCT07203118
- Testing
- HTS 20mg, HTS 30mg, HTS 40mg
- Where
- China
- Volunteers
- 1,444 people
- Sponsor
- Xi'an Xintong Pharmaceutical Research Co.,Ltd.
Hepatitis C, Cryoglobulinaemic Glomerulonephritis
Grazoprevir and Elbasvir Without Ribavirin for 12 Weeks in Patients With HCV-related Cryoglobulinemic Nephropathy
CryoKid is a no-profit, multi-center, single-arm, open-label, pilot study. The study aims to evaluate the tolerability of MK-8742 (Elbasvir) / MK-5172 (Grazoprevir) administrated for 12 weeks without Ribavirin in patients with…
- Trial name
- CRYOKID (NCT03433326)
- Testing
- Elbasvir/Grazoprevir
- Volunteers
- 45 people
- Sponsor
- University of Florence
Chronic Hepatitis B
Lowering Viral Load With Nucleos(T)Ide Analogues Prior to Peginterferon Treatment to Ncrease Sustained Response in CHB
Treatment with a nucleoside analogue and subsequent viral decline has shown to partially restore immune hyporesponsiveness in chronic hepatitis B patients.
- Trial name
- PEGON (NCT01532843)
- Testing
- PegIFN alfa-2b
- Where
- 4 sites in China, Netherlands
- Volunteers
- 82 people
- Sponsor
- Foundation for Liver Research
HIV, Hepatitis B
Pan-Viral Screening and Linkage to Care Among GBMSM and Trans Women in Spain
The World Health Organization (WHO) aims to eliminate viral hepatitis as a public health threat by 2030, with major reductions in hepatitis B and C incidence and mortality.
- Conditions
- HIV, Hepatitis B, Hepatitis C
- Trial name
- PAN-TESTATE (NCT07085715)
- Testing
- Online self-sampling testing strategy to enhance pan-viral testing (HBV, HCV, HIV)
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- Fundació Institut Germans Trias i Pujol
Chronic Hepatitis C
Efficacy and Safety of Ypeginterferon Alfa-2b in Chronic Hepatitis C
This study is a multi-center, randomized, open-label and positive controlled Phase II Clinical trial to assess the efficacy and safety of Ypeginterferon alfa-2b (with Ribavirin), once a week, in 3 dose-groups respectively, for…
- Trial name
- PEGIFN (NCT01140997)
- Testing
- Ypeginterferon alfa-2b, Peginterferon alfa-2a
- Where
- 38 sites in China
- Volunteers
- 211 people
- Sponsor
- Xiamen Amoytop Biotech Co., Ltd.
Chronic Hepatitis B
Study to Evaluate the Safety, Tolerability, and Efficacy of Vesatolimod in Combination With Tenofovir Disoproxil Fumarate (TDF) in Adults With Chronic Hepatitis B (CHB) Infection Who Are Currently Not Being Treated
The primary objectives of this study are to evaluate the safety, tolerability, and efficacy of vesatolimod (formerly GS-9620) in adults with chronic hepatitis B (CHB) infection who are currently not being treated.
- Trial name
- NCT02579382
- Testing
- TDF, Vesatolimod
- Where
- 21 sites in United States, Canada and 6 more
- Volunteers
- 192 people
- Sponsor
- Gilead Sciences
Liver Transplant, Hepatitis C
Proteogenomic Monitoring and Assessment of Liver Transplant Recipients
This study is being done to test blood, urine and tissue samples to see if this can help decide if CKD (Chronic Kidney Disease), AR (Acute Rejection) and HCV (Hepatitis C Virus) can be identified in its early stages.
- Conditions
- Liver Transplant, Hepatitis C, Chronic Kidney Disease, Acute Rejection
- Trial name
- "Mini-Liver" (NCT01644903)
- Where
- United States
- Volunteers
- 1,000 people
- Sponsor
- Northwestern University
Chronic Hepatitis b
Evaluation of The Safety, Efficacy and Pharmacokinetic Characteristics of GST-HG141 Tablets
A Randomized, Double-blind, Placebo-controlled and Multicenter Phase Ⅱ Clinical Trials To Evaluate the Safety, Efficacy and Pharmacokinetics of GST-HG141 Tablets in Treated Chronic Hepatitis B (CHB) Patients With Low Viremia.
- Trial name
- NCT05637541
- Testing
- GST-HG141
- Where
- China
- Volunteers
- 90 people
- Sponsor
- Fujian Akeylink Biotechnology Co., Ltd.
Hepatitis B
Acceptability of Hepatitis B Vaccination in General Population
The present study is conducted in order to assess the acceptability of Hepatitis B vaccination in French general population before and after reimbursement of the paediatric vaccine InfanrixHexa.
- Trial name
- PopCorn (NCT01782794)
- Testing
- Data collection
- Volunteers
- 2,413 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Hepatitis C
Study to Determine the Effect of BMS-791325 on the ECG QTcF Interval in Healthy Subjects
The purpose of this study is to determine whether BMS-791325 has an effect on the electrocardiogram (ECG) interval QT corrected for Fridericia's method (QTcF).
- Trial name
- NCT02084953
- Testing
- BMS-791325, Moxifloxacin
- Where
- United States
- Volunteers
- 59 people, healthy volunteers welcome
- Sponsor
- Bristol-Myers Squibb
Chronic Hepatitis C, Hepatitis C
Study of AT-527 in Healthy and HCV-Infected Subjects
This study has multiple parts. It will assess the safety, tolerability and pharmacokinetics (PK) of AT-527 in healthy subjects and subjects infected with hepatitis C virus (HCV).
- Conditions
- Chronic Hepatitis C, Hepatitis C, Hepatitis C, Chronic
- Trial name
- NCT03219957
- Testing
- AT-527
- Where
- 2 sites in Belgium, Moldova
- Volunteers
- 88 people, healthy volunteers welcome
- Sponsor
- Atea Pharmaceuticals, Inc.
Chronic Hepatitis B Infection
Efficacy and Safety of Ricovir® in Maintaining Durability of Viral Response in Chronic Hepatitis B Patients Who Have Been Treated With Viread® and Have Undetectable HBV DNA in Serum
This is a phase IV, open label, historical controlled comparative study to evaluate the efficacy and safety of Ricovir® in maintaining durability of viral response in CHB patients who have been treated with Viread® and have…
- Trial name
- NCT05355467
- Testing
- Tenofovir disoproxil fumarate, Historical Data
- Where
- Taiwan
- Volunteers
- 40 people
- Sponsor
- Mylan (Taiwan) Ltd
Chronic Hepatitis C Genotype 1B, Metabolic Syndrome
Open-Label Efficacy and Safety Study of the Elbasvir/ Grazoprevir Fixed Dose Combination Patients With Chronic HCV GT1b
This is a multi-center, open-label trial of Elbasvir/ Grazoprevir 50/100 mg fixed dose combination 12 week treatment aimed to evaluate SVR12 in treatment naïve patients with chronic hepatitis C (genotype 1b) infection, associated…
- Conditions
- Chronic Hepatitis C Genotype 1B, Metabolic Syndrome, Fibrosis, Liver, Cirrhoses, Liver
- Trial name
- NCT03222167
- Testing
- Elbasvir/ Grazoprevir 50/100 mg fixed dose combination
- Where
- Kazakhstan
- Volunteers
- 60 people
- Sponsor
- Institute Of Cardiology & Internal Diseases, Kazakhstan
Healthy
Clinical Trial to Assess the Safety and Pharmacokinetics of DA-2802 319mg and Viread 300mg in Healthy Male Volunteers
This Phase I clinical study is to evaluate the safety and pharmacokinetics of DA-2802 319mg and Viread 300mg after a single oral dose in healthy male volunteers.
- Trial name
- NCT02557594
- Testing
- Viread 300mg, DA-2802 319mg
- Where
- South Korea
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Dong-A ST Co., Ltd.
BCLC Stage B Hepatocellular Carcinoma, BCLC Stage C Hepatocellular Carcinoma
Pembrolizumab (MK-3475) in Hepatocellular Carcinoma
This will be a Phase II study investigating single agent pembrolizumab (Keytruda®) as a second-line therapy for subjects with hepatocellular carcinoma (HCC) who either progressed on or after sorafenib or did not tolerate…
- Conditions
- BCLC Stage B Hepatocellular Carcinoma, BCLC Stage C Hepatocellular Carcinoma, Hepatitis C Infection, Refractory Liver Carcinoma
- Trial name
- NCT02940496
- Testing
- Elbasvir/Grazoprevir, Laboratory Biomarker Analysis, Pembrolizumab
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- M.D. Anderson Cancer Center
Hepatitis B, Portal Hypertension
Atorvastatin Use and Portal Hypertension in Patients With Hepatitis B Virus-related Liver Cirrhosis: A Randomized Controlled Trial
To evaluate whether atorvastatin can improve portal hypertension in patients with chronic hepatitis B related compensated cirrhosis with portal hypertension
- Trial name
- STAPH (NCT05483894)
- Testing
- Atorvastatin 10mg
- Volunteers
- 36 people
- Sponsor
- Samsung Medical Center
Healthy
A Study to Evaluate the Reactogenicity, Safety, and Immunogenicity of the Third Generation Hepatitis B Vaccine
A single center, randomized, double blinded phase I/IIa exploratory study to evaluate reactogenicity, safety, immunogenicity and dose-response of a new hepatitis B vaccine in human adult
- Trial name
- NCT02692170
- Testing
- CVI-HBV-001, Conventional Hepatitis B vaccine (20 μg)
- Volunteers
- 75 people, healthy volunteers welcome
- Sponsor
- Aribio Lab Co., Ltd.
Hepatitis C
Efficacy and Safety of Adding Alisporivir (DEB025) to Peginterferon (IFN) Alfa-2a (Peg-IFN Alfa-2a) and Ribavirin in Chronic HCV Genotype 1 Patients Who Relapsed or Did Not Respond to Previous Treatment
The study is to investigate whether participants with hepatitis C virus (HCV) genotype 1 who have a history of non-response/relapse to peginterferon alfa-2a (PEG) and ribavirin (RBV) may benefit from treatment with triple therapy…
- Trial name
- NCT01183169
- Testing
- Alisporivir, Peginterferon alfa-2a, Ribavirin
- Where
- 75 sites in United States, Australia and 12 more
- Volunteers
- 459 people
- Sponsor
- Debiopharm International SA
Hepatitis C, Chronic
Viral Kinetic Study With Viramidine in Therapy-Naive Patients With Chronic Hepatitis C
The purpose of this study is to examine the rapid virologic response (RVR) at combination therapy (CT) Week 4 between groups receiving a standard combination peginterferon alfa-2b/viramidine dosing regimen versus a cohort that…
- Trial name
- NCT00305383
- Testing
- Viramidine, Peginterferon alfa-2b
- Where
- 11 sites in United States
- Volunteers
- 100 people
- Sponsor
- Bausch Health Americas, Inc.
Chronic Hepatitis Delta
Peginterferon Lambda and Lonafarnib Boosted With Ritonavir 48-Week Combination Therapy for Delta Hepatitis
Background: Chronic hepatitis D is a serious liver disease caused by a virus. Currently, no medications are approved to treat chronic hepatitis D. Objective: To test a combination of 3 drugs in people with chronic hepatitis D.
- Trial name
- NCT05953545
- Testing
- Peginterferon Lambda
- Where
- United States
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.